Jason Haas insider trades

Open-market stock purchases and sales by Jason Haas, Director at Ligand Pharmaceuticals Inc, from SEC Form 4 filings since Oct 12, 2021.

Track record: 0% of 3 scored buys are up 5% or more since purchase, averaging -71%.

Recent trades

DateStockTradeValue
Aug 12, 2026LGND Ligand Pharmaceuticals IncBought (not open market)$316K
Aug 12, 2026LGND Ligand Pharmaceuticals IncSold$2.1M
Aug 12, 2026LGND Ligand Pharmaceuticals IncBought (not open market)—
Jun 12, 2026LGND Ligand Pharmaceuticals IncSold$765K
Jun 12, 2026LGND Ligand Pharmaceuticals IncSold$886K
Jun 12, 2026LGND Ligand Pharmaceuticals IncBought (not open market)—
Jun 12, 2026LGND Ligand Pharmaceuticals IncBought (not open market)—
Jun 5, 2026LGND Ligand Pharmaceuticals IncBought (not open market)—
Jun 5, 2026LGND Ligand Pharmaceuticals IncBought (not open market)—
May 8, 2026ODTX Odyssey Therapeutics, IncBought$20K

Companies traded

  • LGND Ligand Pharmaceuticals Inc: 3 sales, last Aug 12, 2026
  • ODTX Odyssey Therapeutics, Inc: 1 buy, last May 8, 2026
  • SYRS Syros Pharmaceuticals, Inc: 3 buys, 1 sale, last Nov 18, 2024

Get free alerts when Jason Haas files a new trade →